A Phase 1 interventional study of ORM-12741 in Healthy, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-11-25.
Sponsored by Orion Corporation, Orion Pharma · Phase 1 and Interventional
The purpose of the study is to evaluate the effect of ORM-12741 on receptor occupancy by positron emission tomography with different doses and plasma concentrations. The pharmacokinetic profile and safety will also be evaluated.
Orion Corporation, Orion Pharma is the lead sponsor of 100 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Orm-12741
Drug: ORM-12741
Single dose as a capsule, oral administration
Receptor occupancy
Time frame: 1 day
Pharmacokinetic variables including peak concentration in plasma, time to peak concentration, area under the plasma concentration-time curve
Time frame: 1 day
Safety variables including blood pressure, heart rate, electrocardiogram, physical examination, laboratory safety variables (haematology, chemistry, serology, urinanalysis) and adverse events.
Time frame: During the study
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma